210 related articles for article (PubMed ID: 28315066)
21. Clinical significance of HER2-positive and triple-negative status in small (≤ 1 cm) node-negative breast cancer.
Gorshein E; Klein P; Boolbol SK; Shao T
Clin Breast Cancer; 2014 Oct; 14(5):309-14. PubMed ID: 24703318
[TBL] [Abstract][Full Text] [Related]
22. Differential expression of epithelial–mesenchymal transition and stem cell markers in intrinsic subtypes of breast cancer.
Pomp V; Leo C; Mauracher A; Korol D; Guo W; Varga Z
Breast Cancer Res Treat; 2015 Nov; 154(1):45-55. PubMed ID: 26467042
[TBL] [Abstract][Full Text] [Related]
23. Prognostic value of breast cancer subtypes on breast cancer specific survival, distant metastases and local relapse rates in conservatively managed early stage breast cancer: a retrospective clinical study.
Sanpaolo P; Barbieri V; Genovesi D
Eur J Surg Oncol; 2011 Oct; 37(10):876-82. PubMed ID: 21824742
[TBL] [Abstract][Full Text] [Related]
24. Sterile, abscess-like cerebral lesion during trastuzumab therapy after HER2 status switch in a triple negative breast cancer patient: a case report and literature review.
Mezei T; Hajdu M; Czigléczki G; Lotz G; Kocsis J; Kulka J; Horváth A
BMC Cancer; 2020 Jul; 20(1):615. PubMed ID: 32611325
[TBL] [Abstract][Full Text] [Related]
25. MMP11 and CD2 as novel prognostic factors in hormone receptor-negative, HER2-positive breast cancer.
Han J; Choi YL; Kim H; Choi JY; Lee SK; Lee JE; Choi JS; Park S; Choi JS; Kim YD; Nam SJ; Nam BH; Kwon MJ; Shin YK
Breast Cancer Res Treat; 2017 Jul; 164(1):41-56. PubMed ID: 28409241
[TBL] [Abstract][Full Text] [Related]
26. Patterns of breast cancer relapse in accordance to biological subtype.
Ignatov A; Eggemann H; Burger E; Ignatov T
J Cancer Res Clin Oncol; 2018 Jul; 144(7):1347-1355. PubMed ID: 29675790
[TBL] [Abstract][Full Text] [Related]
27. Patterns of regional recurrence according to molecular subtype in patients with pN2 breast cancer treated with limited field regional irradiation.
Cho WK; Park W; Jeong Y; Kim H; Kim N
Jpn J Clin Oncol; 2023 Jan; 53(1):57-62. PubMed ID: 36305299
[TBL] [Abstract][Full Text] [Related]
28. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy.
Nguyen PL; Taghian AG; Katz MS; Niemierko A; Abi Raad RF; Boon WL; Bellon JR; Wong JS; Smith BL; Harris JR
J Clin Oncol; 2008 May; 26(14):2373-8. PubMed ID: 18413639
[TBL] [Abstract][Full Text] [Related]
29. Brain metastases after breast-conserving therapy and systemic therapy: incidence and characteristics by biologic subtype.
Arvold ND; Oh KS; Niemierko A; Taghian AG; Lin NU; Abi-Raad RF; Sreedhara M; Harris JR; Alexander BM
Breast Cancer Res Treat; 2012 Nov; 136(1):153-60. PubMed ID: 22968656
[TBL] [Abstract][Full Text] [Related]
30. The influence of breast cancer subtype on survival after palliative radiation for osseous metastases.
Abdelhakiem MK; Johnstone C; Bergom C; Currey A; Robbins JR
Cancer Med; 2020 Dec; 9(23):8979-8988. PubMed ID: 33146466
[TBL] [Abstract][Full Text] [Related]
31. Histological grade as an alternative to the Ki67 labeling index is only available for luminal-type breast cancers.
Hayashi S; Kitada M; Sato K; Matsuda Y; Ishibashi K; Oikawa K; Miyokawa N; Hirata S
Breast Cancer; 2014 Jan; 21(1):47-51. PubMed ID: 22467403
[TBL] [Abstract][Full Text] [Related]
32. Survival benefit of anti-HER2 therapy after whole-brain radiotherapy in HER2-positive breast cancer patients with brain metastasis.
Zhang Q; Chen J; Yu X; Cai G; Yang Z; Cao L; Hu C; Guo X; Sun J; Chen J
Breast Cancer; 2016 Sep; 23(5):732-9. PubMed ID: 26267412
[TBL] [Abstract][Full Text] [Related]
33. Integration of a Radiosensitivity Molecular Signature Into the Assessment of Local Recurrence Risk in Breast Cancer.
Torres-Roca JF; Fulp WJ; Caudell JJ; Servant N; Bollet MA; van de Vijver M; Naghavi AO; Harris EE; Eschrich SA
Int J Radiat Oncol Biol Phys; 2015 Nov; 93(3):631-8. PubMed ID: 26461005
[TBL] [Abstract][Full Text] [Related]
34. Overall survival and the response to radiotherapy among molecular subtypes of breast cancer brain metastases treated with targeted therapies.
Miller JA; Kotecha R; Ahluwalia MS; Mohammadi AM; Chao ST; Barnett GH; Murphy ES; Vogelbaum MA; Angelov L; Peereboom DM; Suh JH
Cancer; 2017 Jun; 123(12):2283-2293. PubMed ID: 28192598
[TBL] [Abstract][Full Text] [Related]
35. The Effect of Molecular Subtype and Residual Disease on Locoregional Recurrence in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Postmastectomy Radiation.
Yang TJ; Morrow M; Modi S; Zhang Z; Krause K; Siu C; McCormick B; Powell SN; Ho AY
Ann Surg Oncol; 2015 Dec; 22 Suppl 3(Suppl 3):S495-501. PubMed ID: 26130454
[TBL] [Abstract][Full Text] [Related]
36. Pattern of distant metastasis in molecular subtypes of carcinoma breast: An institutional study.
Kunikullaya SU; Poddar J; Sharma AD; Patel S
Indian J Cancer; 2017; 54(1):327-332. PubMed ID: 29199716
[TBL] [Abstract][Full Text] [Related]
37. Molecular class as a predictor of locoregional and distant recurrence in the neoadjuvant setting for breast cancer.
Vargo JA; Beriwal S; Ahrendt GM; Soran A; Johnson RR; McGuire K; Bhargava R
Oncology; 2011; 80(5-6):341-9. PubMed ID: 21791944
[TBL] [Abstract][Full Text] [Related]
38. Breast cancer subtype and distant recurrence after ipsilateral breast tumor recurrence.
Ishitobi M; Okumura Y; Arima N; Yoshida A; Nakatsukasa K; Iwase T; Shien T; Masuda N; Tanaka S; Tanabe M; Tanaka T; Komoike Y; Taguchi T; Nishimura R; Inaji H
Ann Surg Oncol; 2013 Jun; 20(6):1886-92. PubMed ID: 23292516
[TBL] [Abstract][Full Text] [Related]
39. Association between rim enhancement of breast cancer on dynamic contrast-enhanced MRI and patient outcome: impact of subtype.
Schmitz AM; Loo CE; Wesseling J; Pijnappel RM; Gilhuijs KG
Breast Cancer Res Treat; 2014 Dec; 148(3):541-51. PubMed ID: 25376743
[TBL] [Abstract][Full Text] [Related]
40. Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome.
Lobbezoo DJ; van Kampen RJ; Voogd AC; Dercksen MW; van den Berkmortel F; Smilde TJ; van de Wouw AJ; Peters FP; van Riel JM; Peters NA; de Boer M; Borm GF; Tjan-Heijnen VC
Breast Cancer Res Treat; 2013 Oct; 141(3):507-14. PubMed ID: 24104881
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]